

Jeremy Carlier

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10216857/publications.pdf>

Version: 2024-02-01

39
papers

1,022
citations

430874

18
h-index

434195

31
g-index

39
all docs

39
docs citations

39
times ranked

1157
citing authors

#	ARTICLE	IF	CITATIONS
1	3F- β -pyrrolidinovalerophenone (3F- β -PVP) in vitro human metabolism: Multiple in silico predictions to assist in LC-HRMS/MS analysis and targeted/untargeted data mining. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2022, 1193, 123162.	2.3	11
2	Acute Intoxications and Fatalities Associated With Benzimidazole Opioid (Nitazene Analog) Use: A Systematic Review. <i>Therapeutic Drug Monitoring</i> , 2022, 44, 494-510.	2.0	30
3	In silico, in vitro, and in vivo human metabolism of acetazolamide, a carbonic anhydrase inhibitor and common α -diuretic and masking agent in doping. <i>Archives of Toxicology</i> , 2022, 96, 1989-2001.	4.2	9
4	A 2017-2019 Update on Acute Intoxications and Fatalities from Illicit Fentanyl and Analogs. <i>Journal of Analytical Toxicology</i> , 2021, 45, 537-554.	2.8	29
5	In silico prediction, LC-HRMS/MS analysis, and targeted/untargeted data-mining workflow for the profiling of phenylfentanyl in vitro metabolites. <i>Talanta</i> , 2021, 235, 122740.	5.5	20
6	Pyrrolidinyl Synthetic Cathinones β -PHP and 4F- β -PVP Metabolite Profiling Using Human Hepatocyte Incubations. <i>International Journal of Molecular Sciences</i> , 2021, 22, 230.	4.1	9
7	Monitoring Perinatal Exposure to Cannabis and Synthetic Cannabinoids. <i>Therapeutic Drug Monitoring</i> , 2020, 42, 194-204.	2.0	19
8	Testing Unconventional Matrices to Monitor for Prenatal Exposure to Heroin, Cocaine, Amphetamines, Synthetic Cathinones, and Synthetic Opioids. <i>Therapeutic Drug Monitoring</i> , 2020, 42, 205-221.	2.0	15
9	Monitoring Prenatal Exposure to Buprenorphine and Methadone. <i>Therapeutic Drug Monitoring</i> , 2020, 42, 181-193.	2.0	10
10	Pharmacology of Herbal Sexual Enhancers: A Review of Psychiatric and Neurological Adverse Effects. <i>Pharmaceuticals</i> , 2020, 13, 309.	3.8	11
11	Measurement Uncertainty in Forensic Toxicology. <i>Therapeutic Drug Monitoring</i> , 2020, 42, 653-654.	2.0	0
12	Consequences of COVID-19 Lockdown on the Misuse and Marketing of Addictive Substances and New Psychoactive Substances. <i>Frontiers in Psychiatry</i> , 2020, 11, 584462.	2.6	40
13	Advances in Forensic Toxicology. <i>Current Pharmaceutical Design</i> , 2020, 26, 3779-3780.	1.9	7
14	Ultra-High-Performance Liquid Chromatography-Tandem Mass Spectrometry Assay for Quantifying Fentanyl and 22 Analogs and Metabolites in Whole Blood, Urine, and Hair. <i>Frontiers in Chemistry</i> , 2019, 7, 184.	3.6	60
15	Cannabidiol Adverse Effects and Toxicity. <i>Current Neuropharmacology</i> , 2019, 17, 974-989.	2.9	244
16	Drug-facilitated sexual assaults (DFSA): a serious underestimated issue. <i>European Review for Medical and Pharmacological Sciences</i> , 2019, 23, 10577-10587.	0.7	24
17	Metabolism of the new synthetic cannabinoid EG-018 in human hepatocytes by high-resolution mass spectrometry. <i>Forensic Toxicology</i> , 2018, 36, 304-312.	2.4	10
18	Pharmacodynamic Effects, Pharmacokinetics, and Metabolism of the Synthetic Cannabinoid AM-2201 in Male Rats. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2018, 367, 543-550.	2.5	17

#	ARTICLE	IF	CITATIONS
19	Synthetic cannabinoid BB-22 (QUCHIC): Human hepatocytes metabolism with liquid chromatography-high resolution mass spectrometry detection. Journal of Pharmaceutical and Biomedical Analysis, 2018, 157, 27-35.	2.8	21
20	In vitro and in vivo human metabolism of a new synthetic cannabinoid NM-2201 (CBL-2201). Forensic Toxicology, 2017, 35, 20-32.	2.4	31
21	Identification of New Synthetic Cannabinoid ADB-CHMINACA (MAB-CHMINACA) Metabolites in Human Hepatocytes. AAPS Journal, 2017, 19, 568-577.	4.4	25
22	Distinguishing Intake of New Synthetic Cannabinoids ADB-PINACA and 5F-ADB-PINACA with Human Hepatocyte Metabolites and High-Resolution Mass Spectrometry. Clinical Chemistry, 2017, 63, 1008-1021.	3.2	48
23	In vitro metabolism of new synthetic cannabinoid SDB-006 in human hepatocytes by high-resolution mass spectrometry. Forensic Toxicology, 2017, 35, 252-262.	2.4	7
24	Human Hepatocyte Metabolism of Novel Synthetic Cannabinoids MN-18 and Its 5-Fluoro Analog 5F-MN-18. Clinical Chemistry, 2017, 63, 1753-1763.	3.2	11
25	25Câ€NBOMe and 25Iâ€NBOMe metabolite studies in human hepatocytes, <i>in vivo</i> mouse and human urine with highâ€resolution mass spectrometry. Drug Testing and Analysis, 2017, 9, 680-698.	2.6	43
26	In Vitro Metabolite Profiling of ADB-FUBINACA, A New Synthetic Cannabinoid. Current Neuropharmacology, 2017, 15, 682-691.	2.9	39
27	Quantification of [1-(5-fluoropentyl)-1H-indol-3-yl](naphthalene-1-yl)methanone (AM-2201) and 13 metabolites in human and rat plasma by liquid chromatography-tandem mass spectrometry. Journal of Chromatography A, 2016, 1451, 97-106.	3.7	6
28	<i>In vitro, in vivo</i> and <i>in silico</i> metabolic profiling of 1â€pyrrolidinopentiothiophenone, a novel thiophene stimulant. Bioanalysis, 2016, 8, 65-82.	1.5	44
29	In Vitro Metabolite Profiling of ADB-FUBINACA, A New Synthetic Cannabinoid. Current Neuropharmacology, 2016, , .	2.9	1
30	Quantification of hypoglycin A in serum using aTRAQâ® assay. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2015, 997, 75-80.	2.3	19
31	CannabinoÃdes de synthÃseÃ: mÃ©thodes analytiques. Toxicologie Analytique Et Clinique, 2015, 27, 184-194.	0.1	3
32	A validated method for quantifying hypoglycin A in whole blood by UHPLCâ€HRMS/MS. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2015, 978-979, 70-77.	2.3	24
33	Screening approach by ultra-high performance liquid chromatographyâ€tandem mass spectrometry for the blood quantification of thirty-four toxic principles of plant origin. Application to forensic toxicology. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2015, 975, 65-76.	2.3	43
34	Quantification of Pregabalin Using Hydrophilic Interaction HPLC-High-Resolution MS in Postmortem Human Samples: Eighteen Case Reports. Journal of Analytical Toxicology, 2014, 38, 143-148.	2.8	27
35	Atropine Eye Drops: An Unusual Homicidal Poisoning. Journal of Forensic Sciences, 2014, 59, 859-864.	1.6	10
36	A Validated Method for Quantifying Atractyloside and Carboxyatractyloside in Blood by HPLC-HRMS/MS, a Non-Fatal Case of Intoxication with Atractylis gummifera L.. Journal of Analytical Toxicology, 2014, 38, 619-627.	2.8	11

#	ARTICLE	IF	CITATIONS
37	The principal toxic glycosidic steroids in <i>Cerbera manghas</i> L. seeds: Identification of cerberin, neriifolin, tanghinin and deacetyltanghinin by UHPLC-MS/MS, quantification by UHPLC-PDA-MS. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2014, 962, 1-8.	2.3	19
38	Fatal Case of a 27-Year-Old Male After Taking Iboga in Withdrawal Treatment: GC-MS/MS Determination of Ibogaine and Ibogamine in Iboga Roots and Postmortem Biological Material. <i>Journal of Forensic Sciences</i> , 2013, 58, 1666-1672.	1.6	23
39	Intoxication mortelle Ã l'iboga: quantification de l'ibogaïne et de l'ibogamine dans des racines d'iboga et dans des prélèvements post-mortem par CPG-SM/SM. <i>Toxicologie Analytique Et Clinique</i> , 2012, 24, 39-47.	0.1	2